Besides, antitumour activities of CED in lung cancer rely on the inhibitory activity against the VEGFR family and the platelet-derived growth factor receptor- (PDGFR-) related kinases c-Kit, PDGFR-α, and PDGFR-β [21]. The gene discussed is KDR; the disease is lung carcinoma.